Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa...

Industry: Biotechnology

Sector: Healthcare

Phone: 206-588-0256

Fax: 206 902 9658

Website: www.atossatherapeutics.com

Address:

107 Spring Street, Seattle, United States

Kevrolet Jul. 28 at 10:12 PM

$ATOS

0 · Reply

JDAAT Jul. 28 at 10:02 PM

$ATOS who selling and who is buying at these prices

1 · Reply

Kittyc803 Jul. 28 at 8:45 PM

$ATOS Board become full bearish . Good job 👏 Guess i will be able to buy in the .50s soon . This is why i’m bullish . We will know by xmas if Lilly is all in with second cohort IA imo . 👇 Carry on 🤦‍♂️

3 · Reply

Dragon35 Jul. 28 at 8:24 PM

$ATOS

0 · Reply

Bunster Jul. 28 at 8:18 PM

$ATOS GEEZER. KNOW YOUR POSTER!!!!!!!!!!!

0 · Reply

Bunster Jul. 28 at 8:16 PM

$ATOS

0 · Reply

Geezer54 Jul. 28 at 7:48 PM

$ATOS Certainly strong possibility --- wasn't Biden "Stealth" much of his autopen years!

1 · Reply

Warrens__Buffet_ Jul. 28 at 7:43 PM

$ATOS highly possible Quay is suffering a serious life illness of his own right now. Would explain why he has not been active in anyway to help the company, has been saving his money (no insider buys) and why there has been an utter silence and lack of action. The company internally may not know what to do and are struggling to figure out a gamelan. Meanwhile Quay is focused on being with family in the trying times . Would also explain MPJ doing his absolute best to cover for the company but just sounding like a broken record at this point… they are scared and to be frank, quite helpless. Worth giving some serious thought to.

1 · Reply

Geezer54 Jul. 28 at 7:26 PM

$ATOS I don't even think the Quack would care, or even notice!!! Does he really know there's shareholders? Wouldn't any part of that drive his conscience to address the temperature? He just asks for Yes votes, and then disappears another year...

1 · Reply

zerotrust07 Jul. 28 at 7:17 PM

$ATOS maybe if we all just start putting postive vibes and sayings on here the stock will go up some how sorta kidding ...but I cant help think the negative morale here is making people dump this

3 · Reply

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 9:00 AM EDT - 2 months ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 2 months ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 2 months ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 8:45 AM EDT - 3 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 3 months ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 3 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 3 months ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 25, 2025, 10:05 AM EDT - 4 months ago

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 8:00 AM EDT - 4 months ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 4 months ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:15 AM EDT - 4 months ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Feb 5, 2025, 8:00 AM EST - 6 months ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Jan 30, 2025, 8:17 AM EST - 6 months ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Jan 23, 2025, 8:15 AM EST - 6 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Dec 12, 2024, 8:15 AM EST - 8 months ago

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Dec 11, 2024, 8:15 AM EST - 8 months ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Dec 10, 2024, 9:05 AM EST - 8 months ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Dec 9, 2024, 8:15 AM EST - 8 months ago

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Nov 21, 2024, 8:30 AM EST - 8 months ago

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Nov 20, 2024, 8:30 AM EST - 8 months ago

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Nov 12, 2024, 8:30 AM EST - 9 months ago

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 8:30 AM EST - 9 months ago

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Nov 4, 2024, 6:30 AM EST - 9 months ago

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Oct 31, 2024, 8:15 AM EDT - 9 months ago

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Oct 21, 2024, 8:30 AM EDT - 10 months ago

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Oct 14, 2024, 5:08 PM EDT - 10 months ago

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Oct 1, 2024, 8:30 AM EDT - 10 months ago

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

Sep 10, 2024, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Sep 3, 2024, 8:30 AM EDT - 11 months ago

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Aug 21, 2024, 11:30 AM EDT - 1 year ago

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Jul 2, 2024, 4:15 PM EDT - 1 year ago

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Jun 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Jun 5, 2024, 8:30 AM EDT - 1 year ago

Atossa to Present at the Sidoti Small-Cap Investor Conference

May 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

May 15, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

May 13, 2024, 8:50 AM EDT - 1 year ago

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

Apr 29, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

Apr 15, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Apr 11, 2024, 8:30 AM EDT - 1 year ago

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Apr 9, 2024, 11:59 AM EDT - 1 year ago

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Apr 1, 2024, 4:00 PM EDT - 1 year ago

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

Mar 18, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Kevrolet Jul. 28 at 10:12 PM

$ATOS

0 · Reply

JDAAT Jul. 28 at 10:02 PM

$ATOS who selling and who is buying at these prices

1 · Reply

Kittyc803 Jul. 28 at 8:45 PM

3 · Reply

Dragon35 Jul. 28 at 8:24 PM

$ATOS

0 · Reply

Bunster Jul. 28 at 8:18 PM

$ATOS GEEZER. KNOW YOUR POSTER!!!!!!!!!!!

0 · Reply

Bunster Jul. 28 at 8:16 PM

$ATOS

0 · Reply

Geezer54 Jul. 28 at 7:48 PM

$ATOS Certainly strong possibility --- wasn't Biden "Stealth" much of his autopen years!

1 · Reply

Warrens__Buffet_ Jul. 28 at 7:43 PM

1 · Reply

Geezer54 Jul. 28 at 7:26 PM

1 · Reply

zerotrust07 Jul. 28 at 7:17 PM

$ATOS maybe if we all just start putting postive vibes and sayings on here the stock will go up some how sorta kidding ...but I cant help think the negative morale here is making people dump this

3 · Reply

Geezer54 Jul. 28 at 7:02 PM

$ATOS PGR may have something to do with this!

0 · Reply

Biospec2021 Jul. 28 at 6:43 PM

$ATOS Everyone talking about CELC and good for that ticker. Was a combo deal just as Kitty mentioned but still gives rise to hope ATOS can also follow same path. Think we continue to be on a leash and also continue to follow our evil master for better or worse. Good ole NBI versus ATOS. CORRELATION almost assured until meaningful progress in FDA trials is ACHIEVED? https://www.msn.com/en-us/money/watchlist?tab=Related&id=a3yxxm&ocid=ansMSNMoney11&duration=1D&src=b_secdans&relatedQuoteId=a3yxxm&relatedSource=MlAl

1 · Reply

Jedea Jul. 28 at 6:40 PM

$ATOS

0 · Reply

JLH1903 Jul. 28 at 6:40 PM

$ATOS If the patent owner's response document has been deleted on July 7, we're in for a surprise, and I don't know if it will be positive or negative, but the truth is that there is an important negotiation for the future, and a change that would leave a clearer path in the studies and the guidelines to follow.

0 · Reply

traylindo Jul. 28 at 6:11 PM

$ATOS who is buying this trashhh

1 · Reply

Warrens__Buffet_ Jul. 28 at 5:48 PM

$ATOS 100% agreed. Most here are too blind to see this. They are so convinced on success and refuse to see any other perspective and will get mad when you try and feed them reality. That is the definition of delusional, and those people generally should seek medical help.

0 · Reply

Geezer54 Jul. 28 at 5:34 PM

$ATOS a past due action item! Investigate the Board of Directors! They're as blind as Quay,(Or) As corrupt! I was one who voted 100% No to all counts last year! Even when their misguided summaries were printed! There are methods to oust this Quack!!! When Intas presents a Trojan Horse Takeover, VOTE YES

1 · Reply

JDAAT Jul. 28 at 4:48 PM

$ATOS Dr Quay should gave up his 2025 salary in support of share price or buy 1/2 million shares to show solidarity

2 · Reply

Warrens__Buffet_ Jul. 28 at 4:43 PM

$ATOS while only the board of directors has the power to remove the CEO, I think if we band together as retail SH we can use our leverage to remove Quay. I hope they get to R/S and get denied by SH. Any further vote should also be denied by us, with the condition that the BOD removes Quay. I will take it into my own hands to contact the BOD to begin negotiations letting them know the R/S will not go through as SH unless we see Quay removed. If I get enough interest here I will get the process started. Please comment share for awareness. This process of removal I see as very bullish, thus my tag reflects that for this purpose only.

1 · Reply

NOYES Jul. 28 at 4:39 PM

$ATOS Quay needs to address directly to share holders or stepdown

1 · Reply

Warrens__Buffet_ Jul. 28 at 4:38 PM

$ATOS when Quay said this was the pinnacle of his career, he wasn’t lying. He’s going to milk this company dry with his $3MM yearly pay until he decides it’s time to hang up the towel and pass this dud on to someone else. 🤣🤣🤣

1 · Reply

CJ27969 Jul. 28 at 4:36 PM

$ATOS my favorite part. I wonder if this includes death. Anyone have any insight ?

0 · Reply

Market Cap	108.49M
Revenue (ttm)	0.00
Net Income (ttm)	-25.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	813,822
Avg Vol	1,054,622
Day's Range	N/A - N/A
Shares Out	129.17M
Stochastic %K	23%
Beta	0.90
Analysts	Strong Sell
Price Target	$5.62